The contact system in liver injury

Chandini Rangaswamy1 · Reiner K. Mailer1 · Hanna Englert1 · Sandra Konrath1 · Thomas Renné1

Received: 15 February 2021 / Accepted: 27 May 2021 / Published online: 14 June 2021 © The Author(s) 2021

Abstract
Coagulation is controlled by a delicate balance of prothrombotic and antithrombotic mechanisms, to prevent both excessive blood loss from injured vessels and pathologic thrombosis. The liver plays a pivotal role in hemostasis through the synthesis of plasma coagulation factors and their inhibitors that, in addition to thrombosis and hemostasis, orchestrates an array of inflammatory responses. As a result, impaired liver function has been linked with both hypercoagulability and bleeding disorders due to a pathologic balance of pro- and anticoagulant plasma factors. At sites of vascular injury, thrombus propagation that finally may occlude the blood vessel depends on negatively charged biopolymers, such as polyphosphates and extracellular DNA, that provide a physiological surface for contact activation of coagulation factor XII (FXII). FXII initiates the contact system that drives both the intrinsic pathway of coagulation, and formation of the inflammatory mediator bradykinin by the kallikrein–kinin system. Moreover, FXII facilitates receptor-mediated signalling, thereby promoting mitogenic activities, angiogenesis, and neutrophil stimulation with implications for liver diseases. Here, we summarize current knowledge on the FXII-driven contact system in liver diseases and review therapeutic approaches to target its activities during impaired liver function.

Keywords Contact system · Coagulation · Factor XII · Liver disease · Inflammation

Introduction
Blood coagulation not only is a physiological process required to prevent blood loss following vessel injury, but also contributes to the formation of thrombi that occlude vessels causing thromboembolic diseases, such as stroke and myocardial infarction [1]. The coagulation system depends on sequential proteolytic activation of plasma-borne coagulation factors. Hepatocytes express and secrete most coagulation factors; therefore, bleeding and thrombotic diseases are common risks for liver disease patients. Factor XII (FXII) is a plasma protease that initiates the contact system, that in turn drives the proinflammatory kallikrein–kinin system and the so-called intrinsic pathway of coagulation. In addition to initiating thrombus formation and inflammation, FXII also triggers growth factor-like cell signalling [2]. Together, FXII contributes to vascular permeability, immune cell function, and proliferation with implications for liver inflammation and regeneration, and carcinogenesis. Here, we provide an overview of the FXII-driven contact system in liver inflammation and present current therapeutic approaches to prevent thrombo-inflammation.

Factor XII-driven contact system
Coagulopathy in liver disease is linked to unbalanced expression of plasma proteins that regulate FXII-driven intrinsic coagulation. The intrinsic pathway of coagulation is a proteolytic cascade of plasma serine proteases initiated by contact activation of zymogen FXII. FXII binds to negatively charged surfaces that induce conformational changes leading to autocatalytic cleavage and formation of an active serine protease, activated FXII (FXIIa) [3]. FXIIa-driven sequential activation of factor XI (FXI), factor IX (FIX), and factor X (FX) leads to the conversion of prothrombin to thrombin (assisted by a thrombin feed-forward activation of factor V (FV), factor VIII (FVIII) and FXI). Finally, thrombin mediates the cleavage of fibrinogen to fibrin, which aggregates to fibers and forms blot clots (Fig. 1). In contrast to intrinsic coagulation, mediated by FXIIa, the
extrinsic pathway of coagulation is initiated through exposure of tissue factor (TF). TF binds and activates FVII to FVIIa, leading to a TF:FVIIa complex that activates FIX and FX and is inhibited by TF pathway inhibitor, which is primarily expressed by endothelial cells and platelets. Especially, Ca$^{2+}$-dependent FVII, FIX, FX, and prothrombin require vitamin K-dependent carboxylation of glutamic acid residues by hepatic gamma-glutamyl-carboxylase. FV, FVIII, FXI, FXII, and FXIII, fibrinogen as well as the anticoagulant factors antithrombin III (ATIII) and proteins C and S are synthesized and released by the liver [4]. In contrast to all other coagulation factors listed above, FXII deficiency impairs thrombus formation in vivo [5], but is not associated with hemostatic abnormalities in mammals [6, 7]. Consistently, pharmacological inhibition of FXIIa provides thromboprotection without an increase in therapy-associated bleeding [8–10]. In addition to coagulation, FXIIa is a physiological activator of the kallikrein–kinin system that culminates in the generation of the proinflammatory mediator bradykinin (BK, a peptide hormone). FXIIa proteolytically cleaves plasma prekallikrein (PK), the precursor of the serine protease plasma kallikrein (PKa), and PKa then liberates BK from high molecular weight kininogen (HK). Furthermore, PKa and FXIIa engage in a feedback mechanism amplifying their proteolytic activation.

BK binding to G protein-coupled B1 and B2 bradykinin receptors (B1R and B2R) mediates various proinflammatory effects such as vasodilation, pain sensation, and leukocyte adhesion and chemotaxis [2, 3, 11]. Impaired regulation of the kallikrein–kinin system leads to swelling disorders as seen in hereditary angioedema (HAE), a rare life-threatening disease with recurrent swelling episodes. HAE type I and type II are characterized by deficiency and dysfunctionality, respectively, of C1 esterase inhibitor (C1INH), the major inhibitor of both FXIIa and PKa. As a consequence, PK and HK levels decrease during acute swelling attacks, which instigated the development of B2R inhibitors to attenuate BK-mediated vascular permeability in HAE (see below). Notably, FXII mutations that increase susceptibility for autoactivation or prevent its inhibition through C1INH were identified as causative for HAE type III that has normal C1INH levels [12, 13].

**FXII signalling**

Intrahepatic inflammation and tissue repair are crucial processes for the clinical outcome after liver injury. Liver fibrosis and cirrhosis depend on immune cell recruitment and signal...
transduction pathways that promote hepatic fibrogenesis, such as urokinase plasminogen activator receptor (uPAR) signalling [14, 15]. In addition to FXIIa enzymatic activities, zymogen FXII has biological activity and mediates signalling through interaction of its two epidermal growth factor (EGF)-homologous domains in the N-terminal region with uPAR [16] (Fig. 2). FXII and HK compete for uPAR binding, whereby FXII mediates and HK prevents uPAR signalling [17]. FXII/uPAR interaction depends on Zn$^{2+}$ ions that are released locally from both activated platelets and neutrophils [18]. Furthermore, β1-integrin and EGF receptor engage in FXII/uPAR signalling that mediates extracellular signal-related kinase 1/2 (ERK1/2) and AKT phosphorylation. Through these pathways, FXII zymogen exerts mitogenic activities in endothelial, alveolar, smooth muscle cells, and rat fetal hepatocytes [19, 20]. Due to its proliferative activity, FXII signalling promotes angiogenesis and it has been reported that FXII-deficient mice have fewer skin vessels [17]. Several studies found that FXII signalling induces proinflammatory cytokine production in alveolar cells [21], monocytes [22], macrophages [23], and dendritic cells [24]. The data suggest that FXII signalling plays a role in multiple inflammatory disease settings. Furthermore, recent findings showed that neutrophils express FXII, which promotes their activation in an autocrine manner. FXII deficiency in neutrophils interferes with migration and because the transfer of wild-type bone marrow restores this phenotype, it was shown that FXII from neutrophils, but not plasma, has a role in neutrophil-mediated wound healing [18]. FXII expression has also been found in lung fibroblasts in response to transforming growth factor-β (TGF-β) [25] and can be induced through steroid hormone binding to the F12 promoter via estrogen-responsive elements [26]. Collectively, FXII signalling regulates cell activation in different tissues and promotes inflammatory responses.

The FXII/uPAR-mediated pathway in hepatocytes suggests that FXII autocrine signalling may participate in the complex regulation of hepatocyte proliferation and liver regeneration upon injury. Notably, liver disease has been associated with increased expression of TGF-β [27, 28], which was found to induce FXII in human lung fibroblasts [25]. At least for pulmonary fibrosis, FXII signalling has been shown to activate fibroblasts and might therefore also contribute to the fibrous obstruction and parenchymal loss in late-stage cirrhosis [29]. FXIIa drives proteolytic cleavage of pro-hematocyte growth factor in vitro [30]. To what extent FXII signalling or FXIIa-mediated activation of hematocyte growth factor contributes to liver regeneration in vivo remains to be addressed in future research as few studies have investigated the impact of contact system proteins on liver homeostasis so
far. However, a recent study by Henderson et al. shows that deficiency in HK, but not FXII, FXI, or PK, protects from acetaminophen-induced liver injury [31]. HK cleavage exacerbates drug-mediated hepatotoxicity and promotes neutrophil recruitment and proinflammatory cytokine expression independently from B1R and B2R signalling. Thus, apart from FXII signalling, other contact system proteins may have a role in liver homeostasis.

Contact activation

Proinflammatory and prothrombotic effects of the contact system promote endothelial dysfunction and hypercoagulability which has clinical relevance for liver disease patients. FXIIa initiates these pathways; thus, targeting contact activation that prevents the autocatalytic cleavage of FXII through contact with negatively charged surfaces appears as a promising therapeutic approach in liver disease. FXII and other contact system proteins have been found to assemble on membranes of endothelial cells [16], neutrophils [32], and platelets [33]. Activation of the latter cell types releases negatively charged mediators that trigger FXII contact activation and initiate the downstream proteolytic cascade. Fibrin formation triggered by FXII contact activation is the mechanistic basis of activated partial thromboplastin time (aPTT) clotting assays. For this, non-physiological polyanionic substrates (e.g., the white clay material kaolin, silica or ellagic acid) are used as FXII activators. Consistently, negatively charged biomolecules such as inorganic polyphosphate (polyP), polysaccharides, and DNA have been identified as surfaces for FXII contact activation in vivo [6, 34, 35]. The biopolymer polyP consists of linear chains of orthophosphates connected by energy-rich phosphohydryde bonds. We recently found that polyP in platelets and megakaryocytes is regulated by the phosphate transporter xenotropic and polytropic retrovirus receptor 1 (XPR1) and that platelet-specific XPR1 deficiency causes polyP accumulation and hypercoagulability, and promotes venous and arterial thrombus formation [36]. Procoagulant polyP release has been shown for activated platelets, mast cells, and basophils [37].

In addition to polyP, exposure of another polyanion, extracellular DNA, has been identified to trigger FXII activation in vivo [38]. Several sources for extracellular DNA in circulation have been identified, including leukocytes, mast cells, disintegrating bacteria and viruses, and liver tumor cells [39–42]. Various pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) stimulate neutrophils to cast out their DNA into the extracellular space, forming neutrophil extracellular traps (NETs). Notably, FXII signalling contributes to the release of NETs, but is only facilitated after uPAR translocates to the plasma membrane upon neutrophil activation [18]. Similar to polyP, an array of studies showed that NETs have implications for thrombotic and inflammatory reactions in vivo [35, 43–45]. Soluble DNA, as well as NETs induced by glucose oxide or interleukin (IL)-8 stimulation of purified neutrophils, can bind and activate FXII in vitro [46]. Confocal microscopy of NETs induced by platelet-activated neutrophils showed that the DNA backbone of NETs associates with FXII [35, 46]. However, whether NETs directly trigger FXII contact activation or merely act as a scaffold for the assembly of FXII activators is still unknown [47]. Thrombin generation in the presence of NETs is reduced in FXII- and FXI-deficient plasma, indicating that the FXII–FXI axis mediates the procoagulant activity of NETs, at least in vitro [48]. In addition, we showed that NETs alone are sufficient for vascular occlusions during chronic inflammation in the absence of host enzymes DNase1 and DNase1L3 in vivo [49]. Underlining the importance of NETs for liver inflammation, DNase treatment or inhibition of NETs via genetic ablation of peptidyl arginine deaminase type IV reduces monocyte infiltration and cytokine production in an experimental steatohepatitis model [50]. Thus, cumulative evidence suggests that both platelet polyP release and NET formation provide a surface for FXII contact activation and are involved in pathophysiological liver processes [51, 52].

Dysregulated coagulation in liver disease

The liver synthesizes and secretes most of the pro- and anticoagulant factors into the plasma. Both the extrinsic and intrinsic pathways rely on expression, posttranslational modification, and the release of coagulation factors from hepatocytes. Accordingly, liver disease is associated with variable degrees of coagulation disorders due to alterations in the quality and quantity of coagulation factors [53]. The imbalance in mechanisms regulating coagulation is further enhanced by insufficient hepatic secretion of thrombopoietin, a hormone that induces megakaryocytes to form mature platelets [54]. Aside from decreased pro- and anticoagulant factors, stasis of venous blood flow through damaged liver tissue increases the risk for portal vein thrombosis (PVT) [4]. Thus, alterations of the hemostatic balance are multifactorial and an array of coagulopathies is associated with liver disease. Clinical diagnosis of the hemostatic state in liver patients is difficult because abnormal clotting test results often suggest a hemorrhagic coagulopathy when patients appear rebalanced due to the concomitant deficiency of both pro- and anticoagulant factors. Addressing the shortcoming of the prothrombin time (PT)-based international normalized ratio (INR) in liver patients, thrombin generation tests have been introduced that correct for anticoagulant protein C activity by addition of soluble thrombomodulin [55]. As a result, the perception of
Liver disease as an isolated risk for bleeding changed to a more complex view of liver disease-related coagulopathies including hemorrhagic and thrombotic components [56].

Liver disease is associated with a procoagulant state

The severity of liver disease relates to the deficiency of coagulation factors and delayed clotting times. A prolonged PT is indicative for liver disease, and depletion of factors with a short half-life, e.g., FV and FVII, is used as a prognostic marker for acute liver failure (ALF) [53]. In contrast to ALF, increased PT in chronic liver disease is linked to reduced FVII expression and commonly assessed in prognostic indices, such as Child-Pugh and Mayo end-stage liver disease [57]. Further disease progression additionally prolongs aPTT by insufficient liver synthesis of FXII, FXI, PK, and HK [58]. In mild and moderate cirrhosis, fibrinogen may increase as an acute phase reactant in plasma [59], whereas patients with end-stage liver diseases may display decreased or functionally abnormal fibrinogen [60]. Contrary to clotting test results, bleeding disorders in liver disease patients are uncommon (except for spontaneous leakage and rupture of varices), since synthesis of both pro- and anticoagulant factors is decreased in cirrhosis. However, the significance of thrombotic diseases in cirrhotic patients [61, 62] and a hypercoagulable state in patients with primary biliary cirrhosis and primary sclerosing cholangitis have been reported [63, 64]. Moreover, local venous thrombosis has been attributed to increased liver inflammation and fibrosis, thereby promoting disease progression [65].

Chronic liver inflammation promotes coagulation disorders

Heterogenic etiologies of chronic liver inflammation entail distinct alterations of the contact activation pathway. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the general population. One study showed that 46% of NAFLD patients have thrombotic risk factors that correlate with the extent of hepatic fibrosis [66]. Circulating FVIII, FIX, FXI, and FXII activities were found to be increased in subjects with NAFLD compared to those without NAFLD [67], underlining the impact of the coagulation system for liver disease pathogenesis. Moreover, NAFLD is accompanied by excessive synthesis of cholesterol and free fatty acids, leading to increased release of very-low-density lipoprotein (VLDL) particles into the circulation. The lipoprotein component phosphatidylethanolamine (PE) has been found to trigger FXII contact activation in thrombin generation assays [68], suggesting that elevated phospholipid levels contribute to blood coagulation in dyslipidemia.

In contrast to NAFLD, a direct link between viral hepatitis and impaired coagulation is less clear [69]. However, as with other liver diseases, hepatitis is associated with cardiovascular disease through dysregulated lipoprotein metabolism, which may facilitate PE-driven FXII contact activation and thrombo-inflammation [70, 71]. Consistent with aggravated immune responses, hepatitis is also associated with the occurrence of antiphospholipid syndrome, an autoimmune disorder that increases thrombosis risk through autoantibodies targeting coagulation factors [72]. Besides antiphospholipid syndrome, systemic lupus erythematosus is often diagnosed in patients with autoantibodies that interfere with clinical coagulation tests. Furthermore, case reports in which chronic liver disease patients develop specifically anti-FXII autoantibodies indicate that inhibition of the intrinsic coagulation can also occur secondary to liver inflammation [73]. Thus, inflammatory and thrombotic mechanisms influence each other mutually in chronic liver diseases.

In addition to the procoagulant balance, patients with advanced liver disease show a prevalence for hyperfibrinolysis with low levels of α2-antiplasmin inhibitor and decreased hepatic clearance of tissue plasminogen activator [53]; however, its clinical relevance has been disputed and it is not clear whether changes are directly induced by liver disease or secondary to clotting activation [56]. Notably, consumption of plasminogen increases in ALF and the fibrinolytic protease plasmin exerts detrimental effects on acetylmethophen-induced ALF through HK cleavage [31, 74], suggesting that thrombo-inflammatory pathologies in ALF are associated with extrinsic pathway activation.

Platelet and neutrophil activation in liver disease

In the light of reduced contact system protein synthesis and procoagulant and proinflammatory imbalance in liver patients, the presence of polyanions that drive contact activation has implications for disease progression and hemostatic state. Chronic liver disease is associated with mild to moderate thrombocytopenia and platelet counts fall rarely below the range of 30,000–40,000/mm³ [53]. Altered platelet activatability in liver disease has remained controversial, whereas the formation of platelet–leukocyte complexes is consistently found to be increased [75]. It is currently unknown to what extent platelet-derived polyP increases contact activation in liver disease; however, a comparative study provided evidence for increased platelet activation in cirrhosis through low-grade endotoxemia [76]. On the other hand, formation of neutrophil extracellular traps (NETosis) is increased in acute and chronic liver disease models and aggravates liver injury [77], suggesting that increased activation (e.g., via platelet-neutrophil complexes) and impaired NET clearance contribute to procoagulant and proinflammatory functions of the contact
system in liver disease. Notably, FXII signalling in neutrophils stimulates cell adhesion, migration, and NETosis [18], indicating that FXII facilitates its activation via the induction of NETosis that may contribute to a FXIIa-driven procoagulant state in liver disease.

**Malignancies and extracellular vesicles promote thrombotic diseases**

Chronic liver damage has been associated with an increased risk for liver cancer. While some of the mechanisms that affect the contact system in liver disease may persist in liver cancer patients, others emerge that additionally play a role for the hemostatic state in liver cancer patients. Hepatocellular carcinoma (HCC) is the most common primary liver cancer with an 85–95% prevalence for liver cirrhosis among HCC patients [78]. HCC is the fourth leading cause of cancer-related deaths as it is usually diagnosed at a late stage, thereby limiting therapeutic options [79]. HCC patients have an increased risk for PVT and like other cancers, HCC is also associated with a higher incidence of systemic venous thromboembolism (VTE) [80, 81]. Similar to patients with advanced liver disease, synthesis of coagulation factors and their cognate inhibitors are reduced in HCC patients leading to coagulation disorders that may even change during disease progression. Moreover, endothelial activation and hemodynamic alterations by HCC growth can tip the hemostatic balance towards hypercoagulability. Furthermore, cancer cells can directly promote the coagulation cascade through the production of procoagulant factors, and proinflammatory and proangiogenic cytokines, and by interaction with endothelial and blood cells [82]. Early studies indicated that cancer cells have an impact on contact system activation. FXII, PK, and HK decrease in plasma of patients with metastatic liver cancer and increased contact system activation has been found in ascites from cancer patients [83, 84].

A relatively small number of studies investigated the contact system in liver cancer. However, several lines of evidence suggest that HCC exerts FXII signalling and influences contact activation. Firstly, in HCC-derived HepG2 cells, but not enterococcoidendocrine L cells, FXII and FXIIa promote proliferation [20], suggesting a specific effect of FXII/FXIIa signalling for liver cell proliferation. Further research will show whether FXII/FXIIa regulates HCC growth and liver fibrosis in vivo. Secondly, consumptive deficiency of contact system proteins in ascites and plasma from cancer patients suggests that the tumor microenvironment modulates FXII expression, activation, and FXIIa-driven growth of HCC. Expression of FXII by HepG2 cells is inhibited through the proinflammatory cytokine IL-6, and it has been suggested that FXII acts as a negative acute phase protein [87]. Indeed, the reduction of FXII and PK plasma levels has been reported in a murine sepsis model, in which depletion of PK, but not FXII, is associated with bacterial growth inhibition in *Streptococcus pyogenes* sepsis [88]. Thus, limiting contact system proteins in response to inflammation may have a beneficial effect on anti-HCC immune responses as IL-6 inhibits FXII expression and potentially decreases FXII signalling.

In addition to soluble factors, cancer cells contribute to contact activation and cancer-associated thrombosis through extracellular vesicles (commonly referred to as microvesicles shed by cancer cells as well as endothelial cells, platelets and leukocytes). Microvesicles are heterogeneous, nano-sized vesicles that carry a variety of bioactive molecules (e.g., proteins, mRNA, miRNA, DNA, and lipids) and expose procoagulant factors on their surface [89, 90]. Microvesicles promote coagulation through several mechanisms. Firstly, they expose phosphatidyserine (PS) that supports the assembly of coagulation factors. Likewise, FXII binding, and the consecutive start of the intrinsic coagulation cascade through PS externalization, is mediated by apoptotic cells that are more frequent in proliferating tumors [91]. Secondly, microvesicles express TF on the surface that drives the extrinsic pathway of coagulation and thirdly expose polyP that initiates the contact system [78, 92]. The latter has been shown for prostasomes (microvesicles secreted by prostate cancer cells) that are rich in polyP with a chain length of 200–1000 phosphate moieties. Prostasomes increase thrombin formation in a FXII-dependent manner in prostate cancer patients, whereas genetic and pharmacological inhibition of FXII and polyP abrogates prostasome-induced thrombus formation in vivo [93]. Thus, cancer-associated microvesicles induce a hypercoagulable state through the extrinsic and intrinsic coagulation systems. In cirrhotic HCC patients, the level of endothelial, platelet, leukocyte, and PS-exposing microvesicles is increased compared to that in cirrhotic patients [94], suggesting that HCC aggravates hypercoagulability.

Besides microvesicles, other mediators for contact system activation are abundant in cancer. Tissue necrosis and tumor apoptosis elevate the level of polyP and extracellular DNA in the circulation, originating from the tumor, non-tumoral cells (e.g., neutrophils), and chemotherapy-associated apoptotic cells [95]. Cancer cell-derived extracellular DNA and cytokines induce neutrophilia and activate NET formation, thereby contributing to tumor-associated thrombotic diseases [96]. Moreover, in a recent study by van der Windt et al., NETs have been shown to promote the development of HCC in liver disease [50]. Thus, NETosis and cancer progression influence each other with implications for the cancer-associated hypercoagulable state (Fig. 3).
Therapy and anticoagulation in liver diseases

Systemic inflammation, advanced age, immobility, and low levels of endogenous anticoagulants make patients with liver disease, especially decompensated cirrhosis, more prone to VTE, PVT, atrial fibrillation, and other thrombotic complications [56]. Novel treatment strategies for liver disease-associated coagulation disorders are needed. Inhibition of FXII provides a safe target for thromboprotection without increasing bleeding events [11]. Neutralization of FXIIa and interference with polyP-dependent FXII activation prevent pulmonary thromboembolism, ferric chloride-induced arterial thrombosis, and prostate cancer-associated venous thrombosis in animal models [10, 36, 93]. Moreover, clinical trials are currently performed with FXIIa-blocking antibodies CSL312/garadacimab (CSL Behring). Targeting FXIIa might be beneficial for diseases with aberrant FXIIa activity, e.g., the kallikrein–kinin system in HAE patients and thrombosis-related complications in SARS-CoV-2 infections [97]. Especially, the absence of bleeding tendency by FXIIa blockade may support its use as a safe antithrombotic treatment in liver disease because conventional direct oral anticoagulants that prevent frequently occurring PVT in early-stage disease will become inapplicable in patients with late-stage chronic liver disease [98].

Furthermore, regulating BK signalling in liver disease potentially interferes with inflammation, angiogenesis, proliferation, and tumor autocrine signalling [99]. Consistently, the B2R antagonist icatibant (Firazyr, Takeda) has been approved for HAE and is in trials for several other indications, such as heart failure and SARS-CoV-2 infection, while various other B1R and B2R antagonists are also currently investigated in cancer [99]. Notably, although anti-inflammatory drugs may mitigate procoagulant processes, their use in liver disease patients has not been recommended because of metabolic complications (e.g., hyperlipidemia and hypertriglyceridemia induced by inhibitors of calcineurin and mammalian target of rapamycin) [100]. The degradation of NETs offers another option to reduce inflammation and coagulation via the FXII/NET-axis. Exogenous DNase is used to degrade the DNA backbone of NETs in cystic fibrosis [101] and has been shown to prevent NET clots [49], the progression from liver disease to HCC [50], and cancer cell activation in mice [102].

Overall, liver diseases still pose a large unmet medical need. Novel treatments that reduce hepatic inflammation and reverse coagulation disorders while retaining metabolic liver function in patients are required. Targeting the contact system has the potential to mitigate thrombo-inflammation. In particular, inhibition of FXIIa and NETosis may help early-stage liver disease patients, as this could ameliorate hypercoagulability and decelerate cirrhosis progression, without interfering with hemostasis.
Conclusion

The FXII-driven contact system promotes inflammation and cell signalling; its direct contribution to liver disease however remains to be elucidated. FXII signalling induces mitogenic activity and angiogenesis, whereas the proteolytic activity of FXIIa triggers BK-mediated inflammation and elicits a prothrombotic state. In liver disease and HCC, coagulation factor synthesis is impaired and a dysregulated contact system potentially contributes to disease progression. Targeting mediators of contact activation like polyP and extracellular DNA poses a novel opportunity for thrombosis prevention including hypercoagulability in liver diseases. Further research is needed to elucidate thrombo-inflammatory mechanisms and to stratify liver disease patients in relation to their thrombotic risk.

Funding  Open Access funding enabled and organized by Projekt DEAL. TR received funding from the German Research Foundation (A11/SFB 877, B8/SFB 841 and P6/KFO306); RKM received funding from the German Heart Foundation (F/34/18).

Declarations

Conflict of interest  The authors declare no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Macfarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 202:498–499
2. Renne T, Stavrou EX (2019) Roles of factor XII in innate immunity. Front Immunol 10:2011
3. Weidmann H, Heikaus L, Long AT, Naudin C, Schluter H, Renne T (2017) The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. Biochim Biophys Acta. Mol Cell Res 1864(11 Pt B):2118–2127
4. Favalaro EJ, Lippi G (2011) Coagulation update: what's new in hemostasis testing? Thromb Res 127(Suppl 2):S13–S16
5. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Galani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202(2):271–281
6. Renne T (2012) The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 34(1):31–41
7. Maas C, Oschatz C, Renne T (2011) The plasma contact system 2.0. Semin Thromb Hemost 37(4):375–381
8. Buller HR, Bethune C, Bhanot S, Galani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI, Investigators F-AT (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372(3):232–240
9. Kuijpers MJ, van der Meijden PE, Feijje MA, Mattheij NJ, May F, Govers-Riemslag J, Meijers JC, Heemskerk JW, Renne T, Cosemann JM (2014) Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 34(8):1674–1680
10. Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamasa A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broome M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renne T (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 6(222):222ra17
11. Maas C, Renne T (2018) Coagulation factor XII in thrombosis and inflammation. Blood. 131(17):1903–1909
12. Bjorkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schonig K, Nothen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, Renne T (2015) Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 128(5):3132–3146
13. de Maat S, Bjorkqvist J, Suffritti C, Wiesenekker CP, Nagtegaal W, Koekman A, van Dooremalen S, Pasterkamp G, de Groot PG, Cicardi M, Renne T, Maas C (2016) Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 138(5):1414–1423 e9
14. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology. 134(6):1655–1669
15. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N, Watanabe A (1999) Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 31(4):703–711
16. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH (2002) Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood. 99(10):3585–3596
17. LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH (2010) Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood. 115(24):5111–5120
18. Stavrou EX, Fang C, Bane KL, Long AT, Naudin C, Kucukal E, Gandhi A, Brett-Morris A, Mumaw MM, Izadmehr S, Merkulova A, Reynolds CC, Alhalabi O, Nayak L, Yu WM, Qu CK, Meyerson HJ, Dubyak GR, Gurkan UA, Nieman MT, Sen Gupta A, Renne T, Schmaier AH (2018) Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J Clin Invest 128(3):944–959
19. Gordon EM, Venkatesan N, Salazar R, Tang H, Schmeidler-Sapiro K, Buckley S, Warburton D, Hall FL (1996) Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A 93(5):2174–2179
20. Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM (1991) Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. Proc Natl Acad Sci U S A 88(10):4382–4385
21. Hess R, Wuijk L, Hesse C, Sewald K, Jonigk D, Wamecke G, Fieghut HG, de Maat S, Maas C, Bonella F, Preisser KT, Weiss B, Schaefer L, Kuebler WM, Markart P, Wygrecka M (2017) Coagulation factor XII regulates inflammatory responses in human lungs. Thromb Haemost 117(10):1896–1907
22. Toossi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD (1992) Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci U S A 89(24):11969–11972

23. Vorlova S, Koch M, Manthey HD, Cochain C, Busch M, Chaudhari SM, Stegner D, Yeperes M, Lorenz K, Nolte MW, Nieswandt B, Zernecke A (2017) Coagulation factor XII induces pro-inflammatory cytokine responses in macrophages and promotes atherosclerosis in mice. Thromb Haemost 117(1):176–187

24. Gobel K, Pankratz S, Asaridou CM, Hermann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug T, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schulmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG (2016) Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun 7:11626

25. Jablonska E, Markart P, Zakrzewicz D, Preissner KT, Wygrecka T (2012) Monocytes, neutrophils, and platelets cooperate to initiation in vivo. Immunity. 34(2):258–268

26. Dooley S, ten Dijke P (2012) TGF-beta in progression of liver disease. Cell Tissue Res 347(1):245–256

27. Mailer RKW, Allende M, Heestermans M, Schweizer M, Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Rose-John S, Sickmann A, Blankenberg S, Huber TB, Kubisch C, Maas C, Gambaryan S, Firsov D, Stavrou EX, Butler L, Renne T. (2021) Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate. Blood. 137(10):1392–1405

28. Shlomi E, Leonard MO, Harrison R, Gant TW, Tonge DP (2018) Multi-method characterization of the human circulating microbiome. Front Microbiol 9:3266

29. Shlomi E, Leonard MO, Harrison R, Gant TW, Tonge DP (2018) Multi-method characterization of the human circulating microbiome. Front Microbiol 9:3266

30. Miyazawa K (2010) Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS J 277(10):2208–2214

31. Henderson MW, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbaugh EM, Wang S, Ilich A, Henderson LM, Sparkenbau...
hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 68(4):1347–1360
51. Balaphas A, Meyer J, Sadoul K, Fontana P, Morel P, Gonelle-Gispert C, Bulher LH (2019) Platelets and platelet-derived extracellular vesicles in liver physiology and disease. Hepatol Commun 3(7):855–866
52. Hilsher MB, Shah VH (2020) Neutrophil extracellular traps and liver disease. Semin Liver Dis 40(2):171–179
53. Amitrano L, Guardascione MA, Brancaccio V, Balzano A (2002) Coagulation disorders in liver disease. Semin Liver Dis 22(1):83–96
54. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zoraf, De Angelis V, Pozzato G (2011) Platelet production and destruction in liver cirrhosis. J Hepatol 54(5):894–900
55. Tripodi A, Primignani M, Mannucci PM, Caldwell SH (2017) Changing concepts of cirrhotic coagulopathy. Am J Gastroenterol 112(2):274–281
56. Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F (2018) Faculty of the 7th International Coagulation in Liver D. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 118(8):1491–1506
57. Green G, Poller L, Thomson JM, Dymock IW (1976) Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 29(11):971–975
58. Paramo JA, Roche E (1993) Hemostasis in advanced liver disease. Semin Thromb Hemost 19(3):184–190
59. Lissman T, Stravitz RT (2015) Rebalanced hemostasis in patients with acute liver failure. Semin Thromb Hemost 41(5):468–473
60. Green G, Thomson JM, Dymock IW, Poller L (1976) Abnormal fibrin polymerization in liver disease. Br J Haematol 34(3):427–439
61. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 101(7):1524–1528 quiz 680
62. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vistrup H, Sorensen HT (2009) Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 104(1):96–101
63. Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A (1997) Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangiitis evaluated by thrombelastography. J Hepatol 26(3):554–559
64. Segal H, Cottam S, Potter D, Hunt BJ (1997) Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology. 25(3):683–688
65. Wanless IR, Wong F, Blends LM, Greig P, Heathcote EJ, Levy G (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 21(5):1238–1247
66. Assy N, Bekirn I, Mejriksy S, Solomon L, Szelab S, Hussein O (2005) Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 11(37):5834–5839
67. Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pilttainen KH, Lundbom N, Rissanen A, Lissila R, Yki-Jarvinen H (2011) Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 31(2):176–183
68. Klein S, Spannagl M, Engelmann B (2001) Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins. Arterioscler Thromb Vasc Biol 21(10):1695–1700
69. Galli L, Gerdes VE, Guasti L, Squizzato A (2014) Thrombosis associated with viral hepatitis. J Clin Transl Hepatol 2(4):234–239
70. Obermayer G, Afonyushkin T, Binder CJ (2018) Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost 16(3):418–428
71. Mendoza-Pinto C, Garcia-Carrasco M, Cervera R (2018) Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant).Curr Rheumatol Rep 20(10):62
72. Chalkiadakis G, Kyriakou D, Tsiaoussis E, Alexandrakis M, Vassilakis S, Kouromalis E (1999) Acquired inhibitors to the coagulation factor XII associated with liver disease. Am J Gastroenterol 94(9):2551–2553
73. Van Dievoet MA, Eechoudh S, Stephene X (2020) Primary hemostasis in chronic liver disease and cirrhosis: what did we learn over the past decade. Int J Mol Sci 21(9):3294
74. Raparelli V, Basili S, Camevale R, Napoliene L, Del Ben M, Nocella C, Barimoccia S, Lucidi C, Talerico G, Riggio O, Violi F (2017) Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology. 65(2):571–581
75. Tang J, Yan Z, Feng Q, Yu L, Wang H (2021) The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol 12:625472
76. Zanetto A, Campello E, Spiezia L, Burra P, Simionii P, Russo FP (2018) Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma. Cancers (Basel) 10(11):450
77. Kim E, Viourt P (2020) Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med 52(12):1898–1907
78. Zanetto A, Senzolo M, Vitala A, Cillo U, Rudoc C, Sartorello F, Spiezza L, Campello E, Rodriguez-Castro K, Ferrarrese A, Farinati F, Burra P, Simionii P (2017) Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 49(4):440–445
79. Connolly GC, Chen R, Hyrient E, Mantry P, Bozorgzadeh A, Abt P, Khorana AA (2008) Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 122(3):290–306
80. Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state. Lancet Oncol 3(1):27–34
81. Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen A, Sandbakk D, Gispert C, Buhler LH (2019) Platelets and platelet-derived extracellular vesicles in liver physiology and disease. Hepatol Commun 3(7):834–843
82. Mendoza-Pinto C, Garcia-Carrasco M, Cervera R (2018) Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep 20(10):62
83. Matsumura Y, Maruo K, Kimura M, Yamamoto T, Konno T, Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H (2000) Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15(4):422–429
84. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, Hack CE (2017) Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood. 90(4):1501–1507
85. Kohler J, Maelitz C, Koczan D, Frank M, Trepsch C, Revenko AS, Crosby JR, Macleod AR, Mikkat S, Oehrmeck-Hecht S (2020)
The contact system proteases play disparate roles in streptococcal sepsis. Haematologica. 105(5):1424–1435

89. Ender F, Freund A, Quecke T, Steidel C, Zamzow P, von Bubnoff N, Gieseler F (2020) Tissue factor activity on microvesicles from cancer patients. J Cancer Res Clin Oncol 146(2):467–475

90. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Sprok HM (2012) Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 10(7):1355–1362

91. Yang A, Chen F, He C, Zhou J, Lu Y, Dai J, Birge RB, Wu Y (2017) The procoagulant activity of apoptotic cells is mediated by interaction with factor XII. Front Immunol 8:1188

92. Lacroix R, Vallier L, Bonifay A, Simoncini S, Mege D, Aubert M, Panicot-Dubois L, Dubois C, Dignat-George F (2019) Microvesicles and cancer associated thrombosis. Semin Thromb Hemost 45(6):593–603

93. Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, Ronquist G, Renne T (2015) The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood. 126(11):1379–1389

94. Campello E, Zanetto A, Spiezia L, Radu CM, Gavasso S, Ferrarese A, Farinati F, Senzolo M, Simioni P (2016) Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res 143:118–121

95. Jahr S, Hentze H, Engelsch S, Hardt D, Fackelmaier FQ, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659–1665

96. Demers M, Wagner DD (2014) NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 40(3):277–283

97. Englert H, Rangaswamy C, Deppermann C, Sperhake JP, Krise C, Schreier D, Gordon E, Konrath S, Haddad M, Pula G, Maier RK, Schlüter H, Kluge S, Langer F, Püschel K, Panousis K, Stavrou EX, Maas C, Renne T, Frye M (2021) Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine. 67:103382

98. Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G (2020) Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. Adv Ther 37(5):1910–1932

99. da Costa PL, Sirois P, Tannock IF, Chammas R (2014) The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 345(1):27–38

100. Burra P, Becchetti C, Germani G (2020) NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep 2(6):100192

101. Law SM, Gray RD (2017) Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review. J Inflamm (Lond) 14:29

102. Albregues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Kutttner V, Brazas E, Maiorino L, Bautista C, Carmona EM, Simioni P, F赞同 DT, Chang K, Lyons SK, Pinkerton KE, Trotman LC, Goldberg MS, Yeh JT, Eggelblad M (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361(6409):eaao4227

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.